CX3CR1 and neoplasm: There was a non-significant trend toward increased PB CX3CR1+ CD8+ T cells in B16 tumor-bearing mice without improvement of survival by combined CTLA-4/PD-L1 blockade therapy (Supplementary Fig. 2).